StockNews.AI
ATRC
StockNews.AI
209 days

AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results

1. AtriCure will announce its Q4 2024 results on February 12, 2025. 2. An audio webcast for results discussion will occur at 4:30 p.m. ET. 3. AtriCure innovates treatments for Afib, affecting over 59 million globally. 4. Their Isolator® Synergy™ is FDA-approved for persistent Afib treatment. 5. AtriCure's devices are market leaders in LAA management and pain relief.

3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings report can influence investor sentiment positively, similar to prior quarters.

How important is it?

Earnings results could impact projections of company performance and stock price.

Why Short Term?

Market reaction expected soon after earnings release, influencing immediate stock performance.

Related Companies

AFIBMDTBSX
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter and full year 2024 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricure.com/events-and-presentations/events. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.

Related News